Literature DB >> 29286443

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions.

Jaroslav Slamecka1, Javier Laurini2, Troy Shirley3, Simon Philipp Hoerstrup4, Benedikt Weber5, Laurie Owen3, Steven McClellan3.   

Abstract

Autologous cell-based therapies got a step closer to reality with the introduction of induced pluripotent stem cells. Fetal stem cells, such as amniotic fluid and membrane mesenchymal stem cells, represent a unique type of undifferentiated cells with promise in tissue engineering and for reprogramming into iPSC for future pediatric interventions and stem cell banking. The protocol presented here describes an optimized procedure for extracting and culturing primary amniotic fluid and membrane mesenchymal stem cells and generating episomal induced pluripotent stem cells from these cells in fully chemically defined culture conditions utilizing human recombinant vitronectin and the E8 medium. Characterization of the new lines by applying stringent methods - flow cytometry, confocal imaging, teratoma formation and transcriptional profiling - is also described. The newly generated lines express markers of embryonic stem cells - Oct3/4A, Nanog, Sox2, TRA-1-60, TRA-1-81, SSEA-4 - while being negative for the SSEA-1 marker. The stem cell lines form teratomas in scid-beige mice in 6-8 weeks and the teratomas contain tissues representative of all three germ layers. Transcriptional profiling of the lines by submitting global expression microarray data to a bioinformatic pluripotency assessment algorithm deemed all lines pluripotent and therefore, this approach is an attractive alternative to animal testing. The new iPSC lines can readily be used in downstream experiments involving the optimization of differentiation and tissue engineering.

Entities:  

Mesh:

Year:  2017        PMID: 29286443      PMCID: PMC5755485          DOI: 10.3791/56003

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

1.  Human amniotic mesenchymal stem cell-derived induced pluripotent stem cells may generate a universal source of cardiac cells.

Authors:  Xiaohu Ge; I-Ning E Wang; Ildiko Toma; Vittorio Sebastiano; Jianwei Liu; Manish J Butte; Renee A Reijo Pera; Phillip C Yang
Journal:  Stem Cells Dev       Date:  2012-06-11       Impact factor: 3.272

2.  A call to standardize teratoma assays used to define human pluripotent cell lines.

Authors:  Franz-Josef Müller; Johanna Goldmann; Peter Löser; Jeanne F Loring
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

3.  Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions.

Authors:  Jaroslav Slamecka; Lilia Salimova; Steven McClellan; Mathieu van Kelle; Debora Kehl; Javier Laurini; Paolo Cinelli; Laurie Owen; Simon P Hoerstrup; Benedikt Weber
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells.

Authors:  Elayne M Chan; Sutheera Ratanasirintrawoot; In-Hyun Park; Philip D Manos; Yuin-Han Loh; Hongguang Huo; Justine D Miller; Odelya Hartung; Junsung Rho; Tan A Ince; George Q Daley; Thorsten M Schlaeger
Journal:  Nat Biotechnol       Date:  2009-10-11       Impact factor: 54.908

5.  Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source.

Authors:  Dörthe Schmidt; Josef Achermann; Bernhard Odermatt; Christian Breymann; Anita Mol; Michele Genoni; Gregor Zund; Simon P Hoerstrup
Journal:  Circulation       Date:  2007-09-11       Impact factor: 29.690

6.  Characterization of pluripotent stem cells.

Authors:  Mercè Martí; Lola Mulero; Cristina Pardo; Cristina Morera; Meritxell Carrió; Leopoldo Laricchia-Robbio; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Nat Protoc       Date:  2013-01-10       Impact factor: 13.491

Review 7.  Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells.

Authors:  N-H Kang; K-A Hwang; S U Kim; Y-B Kim; S-H Hyun; E-B Jeung; K-C Choi
Journal:  Cancer Gene Ther       Date:  2012-06-01       Impact factor: 5.987

8.  Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions.

Authors:  Jeanette Beers; Daniel R Gulbranson; Nicole George; Lauren I Siniscalchi; Jeffrey Jones; James A Thomson; Guokai Chen
Journal:  Nat Protoc       Date:  2012-10-25       Impact factor: 13.491

9.  Trisomy 21 mid-trimester amniotic fluid induced pluripotent stem cells maintain genetic signatures during reprogramming: implications for disease modeling and cryobanking.

Authors:  Caterina Pipino; Sayandip Mukherjee; Anna L David; Michael P Blundell; Steven W Shaw; Peggy Sung; Panicos Shangaris; Jonathan J Waters; Drew Ellershaw; Marina Cavazzana; Gustavo Mostoslavsky; Assunta Pandolfi; Agostino Pierro; Pascale V Guillot; Adrian J Thrasher; Paolo De Coppi
Journal:  Cell Reprogram       Date:  2014-08-27       Impact factor: 1.987

10.  CellNet: network biology applied to stem cell engineering.

Authors:  Patrick Cahan; Hu Li; Samantha A Morris; Edroaldo Lummertz da Rocha; George Q Daley; James J Collins
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

View more
  1 in total

1.  A circular RNA map for human induced pluripotent stem cells of foetal origin.

Authors:  Mario Barilani; Alessandro Cherubini; Valeria Peli; Francesca Polveraccio; Valentina Bollati; Federica Guffanti; Alessandro Del Gobbo; Cristiana Lavazza; Silvia Giovanelli; Nicola Elvassore; Lorenza Lazzari
Journal:  EBioMedicine       Date:  2020-06-20       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.